Iterum Therapeutics plc (ITRMF) › Cash & EquivalentsIterum Therapeutics plc (ITRMF) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2017: $8.48M2018: $44.55M2019: $4.80M2020: $14.51M2021: $27.45M2022: $21.09M2023: $6.07M2024: $24.12M$24.12M2017Cash & Equivalents (USD)2024Fiscal YearCash & EquivalentsChange YoY2024$24.12M+297.4%2023$6.07M-71.2%2022$21.09M-23.2%2021$27.45M+89.2%2020$14.51M+202.2%2019$4.80M-89.2%2018$44.55M+425.1%2017$8.48M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share